Farmas USA

CNAT

Otro chicharrín que se apunta al party

http://finviz.com/quote.ashx?t=CNAT
Las mías son una aburridas, no quieren fiesta :)

SGEN

El dire se ha hinchado a comprar los últimos días entre 34 y 39

http://finviz.com/quote.ashx?t=SGEN&b=2

En el After ACHN subiendo un 5%
:-))
ACHN

Habrá que seguir las que lleva el fondo Baupost Group

http://inbestia.com/analisis/merck-regala-un-239-de-beneficios-a-los-accionistas-de-idenix

http://j3sg.com/Reports/Stock-Insider/Generate-Institution-Portfolio.php?institutionid=3982&DV=yes

NVAX

Novavax Announces Exercise of Option to Purchase Additional Shares and Closing of Public Offering

GAITHERSBURG, Md., June 11, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced the closing of the underwritten public offering priced on Thursday, June 5, 2014.

The company issued 28,750,000 shares of its common stock, including 3,750,000 shares pursuant to the underwriters' option to purchase additional shares. The shares were issued at $4.00 per share resulting in total gross proceeds from this offering of $115,000,000, before deducting the underwriters discount and offering expenses.

Novavax intends to use a portion of the net proceeds from this offering to expand the clinical development of its RSV F-protein nanoparticle vaccine candidate through the initiation of a Phase 2 clinical trial in elderly subjects later this year. This trial has been added to the company's commitment to initiate RSV clinical trials in the pediatric and maternal immunization indications in the fourth quarter of 2014. Together, these three separate Phase 2 trials will advance the development of the RSV F-protein vaccine candidate in all three of its primary indications, supporting the company's goal of accelerating the timelines to first approval. Additionally, the company intends to use certain of the net proceeds for general corporate purposes, the advancement of its influenza vaccine candidates and its pre-clinical research programs, manufacturing and process

------- lo que yo entiendo. - NVAX ha vendido 100 kilos en un tiempo record. - se dan vidilla con los trials para salir al mercado antes. algo bueno de los estudios de NVAX es que esto no son fases de cancer que duran años. Las fases 2 suelen durarles 5-6 meses. edito: 100 kilos no, 115

ZLCS

Hay explicación para que suba un 30% en el after?

Situación actual del mercado de las vacunas para el cáncer cervico uterino
---http://www.vaccinenation.org/2014/06/11/vaccine-asia-live-current-situation-cervical-cancer-vaccines/?utm_campaign=Vaccine%20Nation%20ASIA%202%2011062014.html&utm_medium=email&utm_source=Eloqua#sthash.7zdLm4b4.dpbs

Fase 3 datos demuestran la comparabilidad de los BOW015 de Epirus Remicade ® para el tratamiento de la artritis reumatoide

http://www.businesswire.com/news/home/20140611006485/en/Phase-3-Data-Demonstrate-Comparability-Epirus’-BOW015#.U5jGR9oaySN

Zlcs